market access | pharmaphorum

Saturday 7 February 2026

market access

News

Janssen J&J Johnson and Johnson pharmaceutical companies

NHS lifted Imbruvica restrictions after press campaign

England’s National Health Service has lifted restrictions on Janssen’s blood cancer drug Imbruvica (ibrutinib), after a journalist who was suffering from chronic lymphocytic leukaemia (CLL)

News

Roche’s Alecensa fast-tracked in China

Roche’s Alecensa fast-tracked in China

China's national regulator has granted a rapid approval for Roche’s lung cancer treatment Alecensa just months after European and American approvals, following a revamp of the country's not

News

vertex

Vertex's Orkambi CF drug okayed for funding in Australia

Committee recommends outcomes-based deal

Views & Analysis

Pills on dollar bills

Value-based healthcare: What’s it worth to you?

It takes healthy people to make a healthy society – and that must be taken into account when we are talking about value-based healthcare.

News

NICE1

NICE in talks with Biogen after rejecting SMA drug

NICE wants 'managed access' scheme

News

vertex

CF patients furious as Vertex turns back on NICE

Patients in England could be denied access to drug